ARTICLE
6 September 2020

The IP Podcast (Ep: 14) - Norwegian Life Sciences, The Oslo Cancer Cluster And Life As A Biotech Start-Up

D
Dehns

Contributor

Founded in 1920, Dehns is one of Europe’s largest full service intellectual property firms, with offices in London, Munich, Oslo, Oxford, Bristol, Brighton, Manchester and Birmingham.

In addition to obtaining patent, trade mark and design protection around the world, our services also extend to IP management consulting and dispute resolution. Dehns attorneys have expertise in a wide range of technologies across the engineering, chemistry and biotechnology sectors.

Our clients include private inventors, universities and research institutions, start-ups and SMEs as well as large multinational corporations. We are firmly focussed on delivering clear advice and valuable results at a competitive cost.

Dehns’ straightforward, business-oriented approach combined with technical excellence has made us leaders in our field and we are proud of our top tier rankings.

In this very special podcast, we take a look at the Life Sciences sector in Norway and how this is one of the country's fastest growing sectors, with innovation, funding and IP being central to this
United Kingdom Food, Drugs, Healthcare, Life Sciences

In this very special podcast, we take a look at the Life Sciences sector in Norway and how this is one of the country's fastest growing sectors, with innovation, funding and IP being central to this growth.

To help us explore this sector in detail, we speak to two people heavily involved in the Norwegian Life Sciences scene: Bjørn Klem, General Manager of the Oslo Cancer Cluster (OCC); and Bjørn Steen Skålhegg, CEO of Arctic Pharma, a start-up company developing innovative anti-cancer drugs, and also an OCC member.

Bjørn Klem explains how the OCC supports its members to accelerate the new development of new cancer diagnostics and medicines, and how IP fits in to that process; Bjørn Steen Skålhegg then explains how Arctic Pharma has grown and developed after being spun-out from another company, how IP has played such an important part in its development, and what they've learnt on their journey so far.

Please click here to listen to the podcast.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More